Pipeline specialized for Musculoskeletal Diseases


이뮤노포지㈜는 근골격계 희귀질환 신약 후보물질을 발굴하며, 다수의 신약 파이프라인을 보유하고 있습니다.

  • Home
  • >
  • Pipeline
  • >
  • Pipeline

주요 파이프라인 현황

Identification Indication Market 기초연구
PF1801 DMD Global
BMD Global
Polymyositis Global
Inclusion Body Myositis Global
Senile Sarcopenia Global
PF1802 ALS Global
PF1803 Degenerative Arthritis Global
KF1601 CML Domestic
  • Biological – A novel long acting GLP-1(glucagon-like peptide-1) class drug
  • GLP-1 receptor activation may have a potential therapeutic application as a treatment for diseases that involved in muscle atrophy and muscle wasting.
  • Extended half-life technology, which achieved once weekly formulation by Elastin-Like Polypeptide (ELP) platform
  • Secured Clinical data upto phase 2b for T2B2(type 2 diabetes) patients with proven safety profile.
  • Drug re-positioning global development strategy :
    Targeting various indications involved in muscle atrophy including DMD, BMDand Polymyositis
  • Stage :
    IND submission for phase IIa in DMD

DMD (Duchenne Muscular Dystrophy, 듀시엔형 근이영양증)
BMD (Becker Muscular Dystrophy, 베커형 근이영양증)

  • DMD and BMD are genetic disorders characterized by the progressive loss of muscle
  • Difficulty rising from a lying or sitting position
  • Large calf muscle, Walking on toes
  • BMD is a milder version of DMD
  • the mutated DMD gene fails to produce virtually any functional dystrophin
  • BMD genetic mutations make partially functional dystrophin
Standard Therapy
  • High dose glucocorticoids

Polymyositis (다발성 근염)

  • A rare, idiopathic, inflammatory myopathy
  • Symmetric proximal muscle weakness
  • In severe cases, causes dysphagia or dysphonia
  • Serious threat to the quality of daily life
  • Auto-immune responses in skeletal muscle
  • Lymphocyte infiltration in the muscle
Standard Therapy
  • High dose glucocorticoids
  • Glucocorticoid-induced toxicity

IBM (Inclusion body myositis, 봉입체 근염)

  • A complex disease with degenerative pathological mechanisms as well as autoimmune mediated by T lymphocytes
  • Progressive muscle weakness in distal finger flexor muscles and the quadriceps
  • Unlike other myositis, asymmetric and distal muscle weakness are likely to appear with slow disease progression
  • Inflammatory cells invade the muscle tissue and concentrate between the muscle fibers presenting multiple inclusion bodies that contain cellular material of dead tissue.
Standard Therapy
  • Immunosuppressant drugs
  • Corticosteroid doesn’t work for IBM.

Senile Sarcopenia (노인성 근감소증)

  • Senile sarcopenia is the loss of muscle mass due to the natural aging process
  • Loss of lean muscle mass and decreased muscle size
  • Reduced strength, functional decline and increased risk of falling
  • Senile sarcopenia is likely the result of multiple interacting factors such as changes in hormones, age-related muscle changes, nutrition, and lifestyle
Standard Therapy
  • Currently there are no medication to treat senile sarcopenia
BBB penetration and bio-availability enhanced first-in-classALS therapeutic candidate
BBB penetration and bio-availability enhanced first-in-classALS therapeutic candidate
BBB penetration and bio-availability enhanced first-in-classALS therapeutic candidate
  • Indication
    :ALS (Amyotrophic lateral sclerosis
    (also known as Lou Gehrig's disease, rare disease)
  • ALS
    :Amyotrophic lateral sclerosis is a devastating neurodegenerative disease that results in progressive loss of motoneurons, motor weakness and death within 3-5 years after disease onset.
  • Class
    :Biologics, Dual ligand Fc fusion protein
  • Causing :unknown
  • Global market size expectation :USD 800 million in 2026
  • Status : in vivo PK
  • Next plan : in vivo Efficacy test
Indication: Degenerative arthritis
  • Class: First-in class/ Biologics new drug, dual functional fusion protein
  • Most common degenerative joint disease with extreme pain from joint cartilage destruction or regression
  • Global market: $ 6 billion in 2019 → $ 9 billion in 2024 (CAGR: 8.1%)
  • Novel Disease-modifying osteoarthritis drug (DMOAD)
  • Stable cell line development
New Chemical Entity
  • KF1601 is a rationally designed BCR-ALB inhibitor
Developmental Strategy
  • As a first T315I inhibitor, Ponatinib has been developed.
    However, it shown diverse side effects, including cardiac and vascular events
  • KF1601 has been developing to overcome the side effects of ponatinib
Developmental Stage
  • KF1601 is planned to enter non-clinical development